#USA #New York #Cancer Immunotherapy #TuHURA Biosciences #IFx-2.0

TuHURA Biosciences at the H.C. Wainwright 28th Annual Conference

TuHURA Biosciences, Inc., a leading immuno-oncology firm, is making headlines as it prepares to present its advancements at the H.C. Wainwright 28th Annual Global Investment Conference scheduled for September 14th, 2026, in New York City. Under the leadership of Dr. James A. Bianco, TuHURA is on the frontline of combating cancer with innovative therapies designed to tackle the significant challenges in cancer immunotherapy.

Aiming to Combat Resistance to Therapy

Cancer immunotherapy has transformed cancer management but often faces hurdles due to primary and acquired resistance. TuHURA is pioneering novel therapeutics to address these challenges head-on. Their flagship product, IFx-2.0, is positioned to enhance the efficacy of existing therapies like Keytruda® (pembrolizumab) and is currently being evaluated in a Phase 3 registration trial. The trial involves comparing Keytruda® combined with IFx-2.0 against Keytruda® with a placebo in patients suffering from advanced or metastatic Merkel Cell Carcinoma, an aggressive form of skin cancer.

Expanding Therapeutic Options

In addition to IFx-2.0, TuHURA is also advancing its second product, TBS-2025, aimed at treating a specific molecular subgroup of acute myeloid leukemia (AML). TBS-2025 is currently entering a Phase 1b dose-escalation trial, targeting patients with mutNPM1 r/r AML, a challenging cohort that represents approximately 35% of all AML cases. This dual approach showcases TuHURA’s commitment to providing personalized treatment options in oncology.

Innovative Technology for Next-Level Treatment

One of TuHURA's most promising developments is its bi-specific, bi-functional antibody-drug conjugates (ADCs). Utilizing Delta Opioid Receptor technology, these ADCs aim to target myeloid-derived suppressor cells (MDSCs) that impede the immune system's ability to fight tumors. By inhibiting the suppressive effects of MDSCs within the tumor microenvironment, TuHURA aims to not only prevent T cell exhaustion but also to diminish acquired resistance to both checkpoint inhibitors and cellular therapies.

Commitment to Advancing Oncology

TuHURA's commitment to innovating cancer treatment solutions places it in a unique position within the biotech landscape. As the company gears up for its presentation at the H.C. Wainwright Conference, the broader scientific community and investors alike are eager to hear details about TuHURA's contributions to oncology research and development.

The conference will feature a 'fireside chat' format with opportunities for one-on-one meetings, allowing attendees to gain deeper insights into the company’s strategic direction and groundbreaking technologies.

For those interested in following TuHURA’s progress and insights, an archived webcast of the presentation will be made available on their investor relations page, ensuring that all stakeholders can stay informed on the latest advancements in cancer therapeutics.

In conclusion, TuHURA Biosciences represents the hope and innovation needed in the fight against cancer, and its forthcoming appearance at the H.C. Wainwright Conference marks a significant milestone for the company as it continues to pave the way in immuno-oncology.